|
US7399A
(en)
|
|
1850-05-28 |
|
charles payne |
|
US865A
(en)
|
|
1838-08-01 |
|
Improvement in fire-arms |
|
CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
TW254946B
(https=)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
UA41909C2
(uk)
|
1994-07-22 |
2001-10-15 |
Елі Ліллі Енд Компані |
Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
|
|
US5476932A
(en)
*
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6143764A
(en)
|
1995-11-07 |
2000-11-07 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
|
US6297258B1
(en)
*
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
BR9914167B1
(pt)
|
1998-09-29 |
2011-03-09 |
|
compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
WO2001051919A2
(en)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
|
EP1385551B1
(en)
|
2001-04-06 |
2008-09-03 |
Wyeth |
Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
|
|
ZA200603888B
(en)
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
|
EA007530B1
(ru)
|
2001-06-01 |
2006-10-27 |
Уайт |
Противоопухолевые комбинации
|
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
|
PL370137A1
(en)
|
2001-11-27 |
2005-05-16 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
KR20050037510A
(ko)
|
2002-06-05 |
2005-04-22 |
세다르스-신나이 메디칼 센터 |
키나제 억제제를 사용하는 암 치료 방법
|
|
AU2003248813A1
(en)
|
2002-07-05 |
2004-01-23 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
|
ATE352301T1
(de)
|
2003-04-22 |
2007-02-15 |
Wyeth Corp |
Antineoplastische zusammensetzungen
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
EA010485B1
(ru)
|
2003-07-23 |
2008-10-30 |
Байер Фамэсьютиклс Копэрейшн |
Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
|
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
BRPI0413255A
(pt)
|
2003-08-01 |
2006-10-03 |
Wyeth Corp |
uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
|
|
AU2004267061A1
(en)
|
2003-08-19 |
2005-03-03 |
Wyeth Holdings Corporation |
Process for the preparation of 4-amino-3-quinolinecarbonitriles
|
|
US7399865B2
(en)
*
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
BR0318503A
(pt)
|
2003-09-15 |
2006-09-12 |
Wyeth Corp |
quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
|
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
|
EP1756137A4
(en)
|
2003-11-05 |
2007-10-31 |
Univ Texas |
DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
|
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
|
CN101501211A
(zh)
|
2004-03-31 |
2009-08-05 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
|
AU2005263972A1
(en)
|
2004-07-23 |
2006-01-26 |
Astrazeneca Ab |
Method of predicting the responsiveness of a tumor to erbB receptor drugs
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
|
PE20060608A1
(es)
|
2004-10-13 |
2006-08-22 |
Wyeth Corp |
Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
|
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
ES2364495T3
(es)
|
2005-02-03 |
2011-09-05 |
The General Hospital Corporation |
Método para tratar cáncer resistente a gefitinib.
|
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
|
PL1859793T3
(pl)
|
2005-02-28 |
2011-09-30 |
Eisai R&D Man Co Ltd |
Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
|
|
CA2599445C
(en)
|
2005-03-09 |
2022-05-03 |
Abbott Laboratories |
Diagnostics method for identifying candidate patients for the treatment with trastuzumab
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
US20060235006A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
|
RU2007134908A
(ru)
|
2005-04-14 |
2009-05-20 |
Вайет (Us) |
Применение ингибитора активности киназы рецептора эпидермального фактора роста для лечения пациентов, невосприимчивых к гефитинибу
|
|
US20110045459A1
(en)
|
2005-04-21 |
2011-02-24 |
Mischel Paul S |
Molecular determinants of EGFR kinase inhibitor response in glioblastoma
|
|
CN101166532B
(zh)
|
2005-04-28 |
2011-06-22 |
惠氏公司 |
微粒化的他那普戈特、组合物及其制备方法
|
|
RU2007141654A
(ru)
|
2005-05-12 |
2009-05-20 |
Пфайзер Инк. (US) |
Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
|
|
BRPI0610147A2
(pt)
|
2005-05-25 |
2010-06-01 |
Wyeth Corp |
método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
|
|
CA2608394A1
(en)
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of preparing 3-cyano-quinolines and intermediates made thereby
|
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
|
AU2006270315A1
(en)
|
2005-07-15 |
2007-01-25 |
Wyeth |
Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
|
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
|
EP1931798A1
(en)
|
2005-10-05 |
2008-06-18 |
AstraZeneca UK Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
|
JP2009514870A
(ja)
|
2005-11-04 |
2009-04-09 |
ワイス |
ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
|
|
WO2007056117A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations of temsirolimus and sunitinib malate
|
|
PL1948180T3
(pl)
|
2005-11-11 |
2013-09-30 |
Boehringer Ingelheim Int |
Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
|
|
PT1951274E
(pt)
|
2005-11-24 |
2009-12-14 |
Aicuris Gmbh & Co Kg |
Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
|
|
JP2007145745A
(ja)
*
|
2005-11-25 |
2007-06-14 |
Osaka Univ |
変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
|
|
BRPI0620646A2
(pt)
|
2005-12-22 |
2011-11-22 |
Wyeth Corp |
composição farmacêutica compreendendo tigeciclina e seu uso
|
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
|
CN101415426A
(zh)
*
|
2006-04-07 |
2009-04-22 |
诺瓦提斯公司 |
c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
|
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
|
CN103424541B
(zh)
|
2006-05-18 |
2018-01-30 |
分子压型学会股份有限公司 |
确定针对病状的个性化医疗介入的系统和方法
|
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
|
US20080112888A1
(en)
|
2006-06-30 |
2008-05-15 |
Schering Corporation |
Igfbp2 biomarker
|
|
AU2007299080B2
(en)
|
2006-09-18 |
2013-04-18 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring EGFR mutations
|
|
AU2007305423A1
(en)
|
2006-09-28 |
2008-04-10 |
Follica, Inc. |
Methods, kits, and compositions for generating new hair follicles and growing hair
|
|
US20090317456A1
(en)
|
2006-10-13 |
2009-12-24 |
Medigene Ag |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
|
CA2672828A1
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Methods of treatment
|
|
EP2121018A2
(en)
|
2006-12-13 |
2009-11-25 |
Schering Corporation |
Treating cancer with anti-igf1r antibody 19d12=sch 717454
|
|
WO2008076143A1
(en)
*
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
|
AU2007338754A1
(en)
|
2006-12-21 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
|
CL2008000095A1
(es)
|
2007-01-12 |
2008-05-16 |
Wyeth Corp |
Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
EP2124901B1
(en)
|
2007-02-01 |
2017-07-19 |
Takeda Pharmaceutical Company Limited |
Tablet preparation without causing a tableting trouble
|
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
CA2684265A1
(en)
|
2007-04-19 |
2008-10-30 |
Wellstat Biologics Corporation |
Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
EP3050566B1
(en)
|
2007-09-10 |
2018-11-28 |
Boston Biomedical, Inc. |
A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
|
|
JP2010540459A
(ja)
*
|
2007-09-24 |
2010-12-24 |
トラガラ ファーマシューティカルズ，インク． |
Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
WO2009061349A1
(en)
|
2007-11-05 |
2009-05-14 |
Puretech Ventures |
Methods, kits, and compositions for administering pharmaceutical compounds
|
|
MX2010006854A
(es)
|
2007-12-18 |
2010-09-09 |
Schering Corp |
Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
|
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
|
NZ617520A
(en)
|
2008-02-25 |
2015-05-29 |
Nestec Sa |
Drug selection for breast cancer therapy using antibody-based arrays
|
|
US20100081632A1
(en)
|
2008-03-06 |
2010-04-01 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
|
CA2718918A1
(en)
|
2008-03-25 |
2009-11-26 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
|
WO2009121031A1
(en)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
US20110182888A1
(en)
|
2008-04-08 |
2011-07-28 |
Peter Ordentlich |
Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
|
|
CA2721665C
(en)
|
2008-04-18 |
2017-01-24 |
Reata Pharmaceuticals, Inc. |
Compounds including an anti-inflammatory pharmacore and methods of use
|
|
RS55631B1
(sr)
|
2008-04-18 |
2017-06-30 |
Reata Pharmaceuticals Inc |
Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
|
|
CN102164941B
(zh)
|
2008-04-18 |
2015-05-27 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
|
|
WO2009146216A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
|
WO2009129546A1
(en)
|
2008-04-18 |
2009-10-22 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
|
|
JP2011519868A
(ja)
|
2008-05-05 |
2011-07-14 |
シェーリング コーポレイション |
癌を処置するための化学療法剤の連続投与
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
ES2692769T3
(es)
|
2008-06-17 |
2018-12-05 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
|
ES2449396T3
(es)
|
2008-07-22 |
2014-03-19 |
Trustees Of Dartmouth College |
Cianoenonas monocíclicas y métodos de uso de las mismas
|
|
CN105147713A
(zh)
*
|
2008-08-04 |
2015-12-16 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
|
US20100069340A1
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
|
CN102232117A
(zh)
|
2008-10-14 |
2011-11-02 |
卡里斯Mpi公司 |
描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
|
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
|
BRPI0921407A2
(pt)
|
2008-11-07 |
2019-09-24 |
Enzo Pharmaceuticals Inc |
terapia de combinação seletiva de erbb-3 (her3)
|
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
US20120130144A1
(en)
|
2009-02-04 |
2012-05-24 |
Bipar Sciences, Inc. |
Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
|
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
|
NZ620000A
(en)
|
2009-03-11 |
2015-07-31 |
Auckland Uniservices Ltd |
Prodrug forms of kinase inhibitors and their use in cancer therapy
|
|
SG174382A1
(en)
|
2009-04-06 |
2011-11-28 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
BRPI1015941A2
(pt)
|
2009-07-02 |
2016-04-19 |
Wyeth Llc |
formulações de comprimido de 3-cianoquinolina e uso das mesmas.
|
|
KR20110007985A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011025271A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
KR101190953B1
(ko)
|
2009-08-25 |
2012-10-12 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
KR20110021691A
(ko)
|
2009-08-25 |
2011-03-04 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
JP2013505968A
(ja)
|
2009-10-01 |
2013-02-21 |
シーエスエル、リミテッド |
フィラデルフィア染色体陽性白血病の治療方法
|
|
AU2010316683B2
(en)
|
2009-11-09 |
2015-10-08 |
Wyeth Llc |
Tablet formulations of neratinib maleate
|
|
CN102724962B
(zh)
|
2009-11-09 |
2017-05-17 |
惠氏有限责任公司 |
包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
|
|
MX358013B
(es)
|
2009-11-13 |
2018-08-01 |
Amgen Inc |
Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
|
|
JP2013512882A
(ja)
|
2009-12-07 |
2013-04-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
|
|
WO2011070499A1
(en)
|
2009-12-11 |
2011-06-16 |
Wyeth Llc |
Phosphatidylinositol-3-kinase pathway biomarkers
|
|
CA2787048C
(en)
|
2010-01-13 |
2021-06-22 |
Wyeth Llc |
A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor
|